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Abstract 
Objectives: Radiotherapy plan quality may vary considerably depending on planner’s 
experience and time constraints. The variability in treatment plans can be assessed by 
calculating the difference between achieved and the optimal dose distribution. The achieved 
treatment plans may still be suboptimal if there is further scope to reduce organs-at-risk doses 
without compromising target coverage and deliverability. This study aims to develop a 
knowledge-based planning (KBP) model to reduce variability of volumetric modulated arc 
therapy (VMAT) lung plans by predicting minimum achievable lung volume-dose metrics. 
Methods: Dosimetric and geometric data collected from forty retrospective plans were used 
to develop KBP models aiming to predict the minimum achievable lung dose metrics via 
calculating the ratio of the residual lung volume to the total lung volume. Model accuracy 
was verified by re-planning forty plans. Plan complexity metrics were calculated using 
locally developed script and their effect on treatment delivery was assessed via measurement. 
Results: The use of KBP resulted in significant reduction in plan variability in all three 
studied dosimetric parameters V5, V20 and MLD by 4.9% (p=0.007, 10.8% to 5.9%), 1.3% 
(p=0.038, 4.0% to 2.7%) and 0.9Gy (p=0.012, 2.5Gy to 1.6Gy) respectively. It also increased 
lung sparing without compromising the overall plan quality. The accuracy of the model was 
proven as clinically acceptable. Plan complexity increased compared to original plans 
however the implication on delivery errors was clinically insignificant as demonstrated by 
plan verification measurements. 
Conclusion: Our in-house model for VMAT lung plans led to a significant reduction in plan 
variability with concurrent decrease in lung dose. Our study also demonstrated that treatment 
delivery verifications are important prior to clinical implementation of KBP models. 
Advances in knowledge: in-house KBP models can predict minimum achievable lung dose-
volume constraints for advance-stage lung cancer patients treated with VMAT. The study 
demonstrates that plan complexity could increase and should be assessed prior to clinical 
implementation.    
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Introduction 
Technological advancements in radiotherapy planning and delivery techniques, such as 
volumetric modulated arc therapy (VMAT) have allowed reduction of dose to critical 
structures whilst maintaining target coverage 
1-3
. Nevertheless, achieving the lowest possible 
organ-at-risk (OAR) doses for a given patient geometry remains challenging as there are 
large population variations in OAR and target structure geometries 
4,5
. Several studies 
reported large heterogeneity in treatment plans produced by planners with different 
experience levels 
4-7
. A treatment plan meeting OAR constraints and with adequate target 
coverage may still be considered suboptimal if OAR doses are possible to be further reduced 
without compromising target coverage. 
To reduce variability between planners, different knowledge-based planning (KBP) methods 
have been implemented. KBP utilises prior patients’ geometries, plans and resultant 
dosimetric coverage to estimate lowest achievable OAR doses for prospective patients prior 
to treatment plan optimisation 
8
. KBP offers several benefits including improvements in 
treatment plan quality, reduction of inter-observer variability and improvement of treatment 
planning efficiency 
9-11
. In addition to OAR dose prediction, KBP methods have also been 
used successfully to determine optimal gantry angle for IMRT patients 
12,13
. 
A number of different metrics have been explored for predicting OAR doses prior to 
treatment plan optimisation. The most commonly used metric is an overlap volume histogram 
(OVH) this is used to characterise the 3D spatial relationship between an OAR and a target 
14-
16
. Other metrics can include overlap of OAR volume with target structure(s) 
17
, OAR volume 
within and outside a target structure 
18
 and similarity coefficient between retrospective and 
prospective patents’ geometry 
19
. 
KBP methods have been largely used for prostate and head and neck planning 
8,20-22
,  
however, only a limited number of studies have reported on its benefit for lung cancer 
patients 
8,23
. A study performed by Fogliata et al utilised commercial software (Varian’s 
RapidPlan
TM
) for VMAT lung planning and reported that the RapidPlan
TM
 KBP model 
facilitated achieving the desired clinical constraints in 4% more patients 
8
. Cui et al produced 
an in-house model for predicting lung doses using a line of best fit to the data for patients 
treated with IMRT fields 
23
. In this study, fifteen ring structures from the planning target 
volume (PTV) were produced and the overlap of lungs with each of the rings was used to 
determine V10 (i.e. volume receiving 10Gy), V20 and V30. Furthermore, Zawadzka et al 
developed an in-house model to predict minimum achievable mean lung dose (MLD) for a 
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. They predicted MLD using the dose calculated from 36 equidistance 
fields.  
At the time of writing, none of the studies in the literature include predictions of minimum 
achievable V5 (percentage of lungs receiving a dose of 5Gy) and minimum achievable V20 for 
lung cancer patients treated with VMAT. V5 is a valuable metric as it has been widely 
reported as a predictor of radiation pneumonitis for advanced-stage lung cancer patients (not 
limited to only mesothelioma patients) 
25-28
. V5 constraints are routinely used at our 
institution for all advanced-stage lung cancer patients therefore a KBP modelling study 
involving this metric has been of particular interest to our department and is expected add a 
missing piece to the literature. 
The aim of this study was to develop in-house KBP models to predict minimum lung dose 
constraints for V5, V20, and MLD for a given patient geometry. Combinations of volumes and 
dose volume histogram (DVH) were used to build the models. Of note is the fact that 
treatment plans optimised using the lower bound model to achieve lowest OAR doses could 
produce highly modulated plans, thereby increasing uncertainties in treatment delivery as 
compared to the plan optimised without the model. Furthermore, any error in treatment plan 
delivery could significantly alter delivered dose distributions especially within high dose 
gradient regions. Therefore, an important objective of our study is to verify the treatment 
delivery accuracy of plans produced using KBP models and compare it with the respective 
delivery accuracy of plans optimised without the model so that an optimal trade-off between 
lower OAR dose and plan delivery can be established. In the present study, the produced 
treatment plans were verified using treatment planning and measurements on the 
TrueBeam
TM
 (V2.5 Varian Medical Systems, Palo Alto, CA) linear accelerator which is a 
novel approach not yet reported in the KBP field. 
Methods 
Data Collection 
The clinical patients were planned with RapidArc
®
/VMAT within the Eclipse
TM
 treatment 
planning system (Version 13.7, Varian Medical Systems, Palo Alto, CA) with 6MV beams. 








 for left sided tumours) 
were used avoiding direct entry through the contralateral lung to minimise the dose received 
by it. Plan dose was calculated using the Acuros
®
 algorithm (dose to water) with a uniform 
dose grid of 0.25 cm. The prescribed dose for patients included in the study was 55Gy in 20 
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fractions. Treatment plans were optimised to meet the planning goals as described in Table 1. 
The normal tissue objective (NTO) function was used to limit dose to healthy structures with 
the same priority as the PTV. The NTO is a function in the Eclipse planning system which 
reduces dose to healthy tissue as a function of distance from the PTV’s outer boarder 
29
. 
Automatic NTO settings were used (i.e. distance from target boarder 1.0cm, start dose 105%, 
end dose 60%, and fall-off 0.05) with priority set to 300 manually. 
A total of forty pre-existing treatment plan datasets from our database were used to build the 
models in this study; all were calculated with Acuros algorithm within the same version of 
Eclipse planning system. Volumes (in cubic centimetre (cc)) for numerous of structures 
including gross tumour volume (GTV), PTV, lungs (lungs minus GTV), PTV outside lungs, 
overlap of lungs with PTV, lungs volume cropped back from the PTV by 1 to 5cm (with 1cm 
increment) and field size were collected. Then, dosimetric parameters such as percentage of 
lungs volume receiving 5Gy (V5), V20, and MLD were collected from the Eclipse treatment 
planning system for the above. 
Development of KBP Model 
To determine suitable volumes (including ratio of different volumes (e.g. Lungs/PTV)) for 
our KBP model, correlation coefficients (R
2
) of all collected volumes with the dosimetric 
data (i.e. V5, V20, and MLD) were determined. The commonly used parameters (e.g. overlap 
volume histogram) and number of volumes (e.g. lungs, PTV, lungs within PTV etc) showed 













Lung sidual       1 
V2 is total lung volume excluding GTV and V1 is the total lung cropped back from PTV by 
5cm (V1: Lungs5cmCrop – volume was produced by cropping total lung (total lung = lungs-
GTV) volume extending inside PTV with an additional margin of 5.0cm using the crop 
function within the planning system) demonstrated in Figure 1. Furthermore, in this study, a 
lower bound model was developed to predict lowest achievable volume-dose (Predictvolume-
dose) for a given geometry (i.e. LungResidual). 
cLungmedict sidualDoseVolume  RePr     2 
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The prediction model was developed based on prescription of for 55Gy in 20 fractions 
(typically used in our clinic). However, to use the model for different prescriptions (i.e. 66Gy 
in 33 fractions and 60Gy in 30 fractions), it was normalised using factor ∆ (see equation 3 













     3 
   cLungmedict sidualDoseVolume RePr     4 
Verification of Model Using Treatment Planning 
A total of forty previously treated patients (not included in the training data) were re-planned 
using the values predicted by the models. For re-planning, optimisation objectives for V5, V20 
and MLD were set to achieve the model predicted values, whereas all other objectives were 
kept the same as the original plans. Difference in dosimetric parameters between predicted 
and replanned, predicted and original, replanned and original plan were compared. 
In addition, the prediction accuracy of the normalised model (see equation 4) was assessed by 
reoptimising ten plans from the test dataset (originally prescribed 55Gy in 20 fractions but for 
the validation of model prescription doses were changed within the planning system). The 
difference between predicted and achieved doses were calculated for both 60Gy and 66Gy 
prescriptions. 
Verification of Model Using Treatment Delivery 
All VMAT plans are routinely verified with portal dosimetry measurements on a linear 
accelerator prior to delivering it to patients. All the plans optimised using the KBP model 
were verified by measuring the fluence on the electronic portal imaging device (EPID) panel, 
without  the presence of a patient, and comparing it with the planned fluence in the portal 
dosimetry image prediction software (PDIP) within the Eclipse planning system. Gamma 
analysis (criteria 3%/2mm ≥ 98% (optimal tolerances set locally) or ≥ 95% (mandatory 
tolerance) results were collected and compared with the original plan results to assess the 
effect of KBP on plan delivery. For analysis, lower dose cut-off threshold was set to 20 %, 
the measured and predicted images were auto-aligned and improved gamma evaluation was 
used. 
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Plan Complexity Measurements 
Treatment plan complexity is dependent on the total number of MU and level of modulation 
within a plan. Simpler treatment plans (i.e. lower MU, less modulated with larger leaf pair 
opening) are preferable as these are relatively less dependent on MLC motion/position 
accuracy during delivery 
29
. Highly complex plans generally have higher number of MU, 
which increase treatment delivery time, increase dose to the patient - due to MLC 
transmission - and are more susceptible to interplay effects. A number of treatment plan 
complexity metrics were calculated both for the original plans as well as the plans produced 
using the KBP model. The treatment plan complexity parameters, including MU/Gy, 
MU/Degree, islands below 1cc (i.e. small islands), small aperture score (SAS: calculated as 
the ratio of open leaf pairs where the aperture was less than a defined criterion (2 mm, 5 mm, 
10 mm and 20 mm in our study) to all open leaf pairs (see equation 5) 
30
) were calculated 















)(    5  
where x is the aperture criteria, i is the number of segments in the beam, N is the number of 





To determine the optimal volumes for predicting dose metrics, Pearson correlation coefficient 
values were calculated. All other comparisons were tested for significance using the 
Student’s paired t-test. P-values <0.05 were considered as suggesting statistically significant 




The clinical KBP models were developed to determine the minimum achievable dose metrics 
using the LungResidual volume (Figure 1). A significant reduction in variability in treatment 
plans amongst different planners was observed following the implementation of the model 
(see Table 2 and Figure 3).  
Furthermore, the plans optimised using the model showed significant reduction in dose-
volume in all three, V5, V20 and MLD, dosimetric parameters. The mean difference between 
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predicted and achieved values was reduced from 10.8% to 5.9%, 4.0% to 2.7% and 2.5Gy to 
1.6Gy for V5, V20 and MLD respectively with the model (Figure 3). In Figure 3, it can be 
observed that negative differences indicate that the model predicted values were higher than 
the achieved values and positive differences indicate model predicted values were lower.  
Furthermore, treatment plans produced using the model-predicted values resulted in 
concurrent reduction in all three dosimetric parameters compared to the original plans 
(Figures 4). The average reduction observed in V5, V20 and MLD was 6.6% (range: 0.4% – 
19.78%), 1.1% (range: -0.93% – 7.77%) and 0.7Gy (range: 0.03Gy – 2.38Gy) respectively. 
The reduction in lung doses was achieved without compromising the overall plan quality. All 
test plans were evaluated by a clinician and were deemed acceptable for clinical delivery.  
In addition, the model developed for the prescription used in our clinic (55Gy in 20 fractions) 
was normalised for use with different prescriptions. The normalised model (equation 3) was 
validated for two additional prescriptions (66Gy in 33 fractions and 60Gy in 30 fractions) by 
replanning ten patients. The indicated accuracy of the models were clinically acceptable; 
mean difference between predicted and achieved doses at V5 was 0.5% and 2.3% for 66Gy 
and 60Gy prescriptions respectively and for V20 and MLD it was 2.1% and 1.2Gy for both 
prescriptions respectively (see Figure 5). 
It was noted in the KBP model-based plans that the total number of MU increased 
significantly in majority of plans compared to the original clinical plans (mean increase = 
46.21MU (range: -48MU – 186MU), p= 0.011). Therefore, a number of treatment plan 
complexity metrics were calculated using a locally developed script for both the original and 
re-optimised plans. The results are shown in Table 3. 
The results show that all studied complexity metrics increased significantly in the re-plans 
optimised using KBP models, when compared to the original plan (see Table 3). This 
indicates that KBP plans were relatively highly modulated compared to the original plans. 
Treatment verification measurements performed on linear-accelerators showed that both 
original and KBP plans delivered as planned. Differences in treatment verification 
measurements for all parameters were within the optimal tolerance limits set locally (≥ 98% 
pixels passing with gamma criteria of 3%/2mm) except two arcs from the KBP plans showed 
slightly higher differences with gamma pass rates at 96.9% and 97.2%. However, these were 
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within the mandatory tolerance limit of ≥ 95%; therefore, these plans were deemed as 
clinically acceptable for treatment delivery. 
Discussion 
The aim of treatment planning is to achieve optimal target coverage whist reducing OAR 
doses as low as reasonably achievable without compromising target coverage 
32
. However, in 
routine clinical practice, due to treatment planners’ experience and clinical workload, this is 
not always achieved for all patients 
4-7
. Furthermore, not all plans meeting target coverage 
and OAR constraints are optimal if there are opportunities to minimise OAR doses further 
without compromising target coverage. This balance may be difficult to be achieved 
efficiently in the absence of KBP methods, especially for relatively inexperienced treatment 
planners.  
Building KBP models for lung cancer patients could be more complex compared with some 
other sites (e.g. prostate) as there are large variations in the location, shape, size and 
orientation of lung tumour with respect to OAR volumes. Several combinations of volumetric 
parameters (e.g. PTV and OAR volumes, overlap volumes, field size) and their correlation 
with studied lung dose-volume parameters were evaluated. However, the LungResidual volume 
calculated using total lung volume and the lungs crop back from PTV by 5.0cm (equation 1) 
showed highest correlation with all the studied lung dose-volume parameters. 
Only two studies have reported on the use of in-house KBP modelling for optimising lung 
plans 
23,24
. However, as none of these models predicts minimum dose to V5 and V20 of lungs, 
we felt it was important to develop local models that predict the minimum achievable dose to 
these percentages of lung volumes for a given patients’ geometry. Furthermore, none of the 
studies in the literature has investigated the effect of KBP models on the complexity of plans 
and hence on the delivery of these plans. In this study, accuracy of the models was verified 
using a planning study while the effect of KBP models on plan complexity and delivery was 
assessed by calculating complexity metrics and performing measurements on a linear 
accelerator. 
Our models were built to predict minimum doses to three lung dose parameters for lung 
patients treated with VMAT. This study demonstrated that minimum lung dose-volume 
prediction models can be developed and used in the routine clinical setting. Relatively simple 
and cost effective models reduced variability/heterogeneity in treatment plans significantly 
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compared to the original clinical plans, which was the primary aim of this study. Predicting 
dose-volume parameters prior to optimising a plan could reduce number of 
optimisations/iterations required to achieve the optimal plan and reduce the overall planning 
time. 
Additionally, the treatment planning study performed showed that the use of a KBP model 
led to a larger reduction in V5 as compared to V20 and MLD (Figure 4). The moderate 
reduction observed for the V20 (1.4%) and MLD (0.7Gy) may be attributed to the use of the 
NTO function in the original and re-optimised plans with same priority as PTV. Results from 
number of commercial auto-planning software showed similar results as our in-house 
developed model 
33,34,35
. One of the auto-planning studies reported statistically insignificant 
increased V5 whereas our study showed consistent and significant reduction in this dosimetric 
parameter 
34
. The normalised model (see Equation 4) shows that the model could be used for 
different prescription. 
In addition, we also assessed the accuracy of the model for oesophagus cancers (commonly 
treated with 45Gy and 50Gy in 25 fractions), treated with full-arc geometry but the prediction 
accuracy of V5 was not clinically acceptable. However, prediction accuracy of V20 and MLD 
was clinically acceptable but the difference seen between predicted and achieved dose were 
higher compared to the lung plan. Mean difference between predicted and achieved values for 
50Gy and 45Gy prescriptions were V5 = 29.7% and 30.8%, V20 = 1.8% and 3.4% and MLD = 
2.3Gy and 2.1Gy respectively. This could be due to the difference in the beam geometry. 
Furthermore, it was noted that the largest reduction in all three dosimetric parameters 
investigated was achieved with the use of KBP models in the subset of plans produced by 
relatively less experienced planners, compared to experienced planners (see patient numbers 
2, 4, 17, 19, 30 and 39 in Figure 4), due to not driving optimiser harder. However, almost all 
the original clinical plans considered met planning goals given in Table 1 and therefore 
acceptable, some were not classed as ‘optimal’ as lung dosimetric parameters could be 
reduced further to some extent without compromising target coverage. Some of these plans 
were produced by experienced staff indicates the potential benefits of KBP for all planners. 
In addition, a relatively smaller reduction in the studied parameters was noted in plans where 
lung constraints were either exceeding or were very close to the tolerance levels in the 
original plans as compared with the plans where lung constraints were well within tolerance – 
potentially due to the fact that the original plans were increasingly optimised to bring doses 
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within tolerance. These results indicate the importance and efficiency of KBP modelling for 
this type of patients in reducing OAR dose variability in treatment plans produced by 
planners of variable experience. 
Webb et al and Abdellatif et al reported that plan complexity increases with increasing 
number of small segments, MU/cGy and number of MUs per control point 
36,37
. An increase 
in the total number of MUs seen in the KBP optimised plans warranted further investigation: 
Treatment plan complexity metrics were calculated and delivery verification measurements 
were performed on a linear accelerator. Plan complexity metrics indicated a significant 
increase in smaller islands (i.e. smaller than 1cc), number of MUs per control point and small 
aperture segments in the KBP plans. These plans were optimised to achieve minimum 
achievable doses, rather than generic OAR tolerances; therefore an increase in plan 
complexity was expected. A study by Crowe et al reported that SAS could be used as an 
indicator of level of plan modulation; they showed positive correlation between quality 
assurance (QA) results and SAS was set at 0.5cm 
30
. In this study, SAS at 0.2cm, 0.5cm, 
1.0cm and 2.0cm increased for all studied plans indicating increase in modulation in these 
plans. 
Although the plan complexity parameters for KBP model-based plans were relatively higher 
than the ones of clinical plans, their impact on the measured fluence was relatively minimal 
for the majority of the test plans. Similar results are reported in the literature 
38,39
. The 
measurements showed overall good agreement with the planned fluence except for two arcs 
where differences exceeded the locally determined optimal gamma tolerance limits. These 
measurements showed that KBP may increase modulation and hence affect delivery therefore 
the model must be verified using treatment delivery measurements prior to implementing it 
clinically. Furthermore, in this study, delivery measurements were performed using EPID 
panel (without patient or moving phantom) that do not fully verify the impact of an increase 
in modulation on the robustness of plan. Further investigation, using a moving phantom, is 
needed to quantify the effect of high modulation of the delivery especially for treatment of 
thoracic tumours.   
Finally, the model was implemented clinically in our clinic using the Eclipse scripting tool 
(ESAPI: Eclipse Scripting Application Plugg-In). Planners produce the structure 
(Lungs5cmCrop = crop total lung volume extending inside PTV with an additional margin of 
5.0cm) using the crop function and then run the script within the Eclipse planning system 
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prior to proceeding with plan optimisation. The script displays the minimum achievable 
dosimetric metrics based on the residual lung volume for the selected patient. The predicted 
values are then manually entered in the optimiser (priorities are set within the clinical 
protocol template) during the optimisation of the plan.  
 
Conclusion 
This study showed that a relatively simple knowledge-based planning model can significantly 
reduce variability in lung planning between planners. The clinical implementation of these 
models demonstrated increase in lung sparing. It is however, important to assess plan 
deliverability prior to clinical implementation of such models to ensure that the potential 
increase in plan complexity will not affect the dosimetrical accuracy required. 
  
Predicting minimum achievable dose constraints using in-house KBP models 
Page 13 of 23 
 
References 
1. Mayo CS, Urie MM, Fitzgerald TJ, Ding L, Lo YC, Bogdanov M. Hybrid IMRT for treatment of 
cancers of the lung and esophagus [published online ahead of print 2008/02/11]. Int J Radiat Oncol 
Biol Phys. 2008;71(5):1408-1418. 
2. Oliver M, Gagne I, Popescu C, Ansbacher W, Beckham WA. Analysis of RapidArc optimization 
strategies using objective function values and dose-volume histograms [published online ahead of print 
2009/12/03]. J Appl Clin Med Phys. 2009;11(1):3114. 
3. Rosca F, Kirk M, Soto D, Sall W, McIntyre J. Reducing the low-dose lung radiation for central lung 
tumors by restricting the IMRT beams and arc arrangement [published online ahead of print 
2011/12/19]. Med Dosim. 2012;37(3):280-286. 
4. Nelms BE, Robinson G, Markham J, et al. Variation in external beam treatment plan quality: An inter-
institutional study of planners and planning systems. Practical radiation oncology. 2012;2(4):296-305. 
5. Batumalai V, Jameson MG, Forstner DF, Vial P, Holloway LC. How important is dosimetrist 
experience for intensity modulated radiation therapy? A comparative analysis of a head and neck case 
[published online ahead of print 2012/07/31]. Pract Radiat Oncol. 2013;3(3):e99-e106. 
6. Moore KL, Schmidt R, Moiseenko V, et al. Quantifying Unnecessary Normal Tissue Complication 
Risks due to Suboptimal Planning: A Secondary Study of RTOG 0126 [published online ahead of print 
2015/04/03]. Int J Radiat Oncol Biol Phys. 2015;92(2):228-235. 
7. Berry SL, Boczkowski A, Ma R, Mechalakos J, Hunt M. Interobserver variability in radiation therapy 
plan output: Results of a single-institution study [published online ahead of print 2016/05/08]. Pract 
Radiat Oncol. 2016;6(6):442-449. 
8. Fogliata A, Belosi F, Clivio A, et al. On the pre-clinical validation of a commercial model-based 
optimisation engine: application to volumetric modulated arc therapy for patients with lung or prostate 
cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and 
Oncology. 2014;113(3):385-391. 
9. Fogliata A, Nicolini G, Clivio A, et al. A broad scope knowledge based model for optimization of 
VMAT in esophageal cancer: validation and assessment of plan quality among different treatment 
centers. Radiation oncology (London, England). 2015;10:220-015-0530-0535. 
10. Chang ATY, Hung AWM, Cheung FWK, et al. Comparison of Planning Quality and Efficiency 
Between Conventional and Knowledge-based Algorithms in Nasopharyngeal Cancer Patients Using 
Intensity Modulated Radiation Therapy [published online ahead of print 2016/02/12]. Int J Radiat 
Oncol Biol Phys. 2016;95(3):981-990. 
11. Wang J, Hu W, Yang Z, et al. Is it possible for knowledge-based planning to improve intensity 
modulated radiation therapy plan quality for planners with different planning experiences in left-sided 
breast cancer patients? Radiation oncology (London, England). 2017;12(1):85-017-0822-z. 
12. Pugachev A, Xing L. Incorporating prior knowledge into beam orientation optimization in IMRT. 
International journal of radiation oncology, biology, physics. 2002;54(5):1565-1574. 
13. Zhang X, Li X, Quan EM, Pan X, Li Y. A methodology for automatic intensity-modulated radiation 
treatment planning for lung cancer. Physics in Medicine and Biology. 2011;56(13):3873-3893. 
14. Wu B, Ricchetti F, Sanguineti G, et al. Patient geometry-driven information retrieval for IMRT 
treatment plan quality control. Medical physics. 2009;36(12):5497-5505. 
15. Kazhdan M, Simari P, McNutt T, et al. A shape relationship descriptor for radiation therapy planning. 
Med Image Comput Comput Assist Interv. 2009;12(Pt 2):100-108. 
16. Wu B, Pang D, Simari P, Taylor R, Sanguineti G, McNutt T. Using overlap volume histogram and 
IMRT plan data to guide and automate VMAT planning: a head-and-neck case study. Med Phys. 
2013;40(2):021714. 
17. Hunt MA, Jackson A, Narayana A, Lee N. Geometric factors influencing dosimetric sparing of the 
parotid glands using IMRT. International journal of radiation oncology, biology, physics. 
2006;66(1):296-304. 
18. Yuan L, Ge Y, Lee WR, Yin FF, Kirkpatrick JP, Wu QJ. Quantitative analysis of the factors which 
affect the interpatient organ-at-risk dose sparing variation in IMRT plans. Medical physics. 
2012;39(11):6868-6878. 
19. Schreibmann E, Fox T. Prior-knowledge treatment planning for volumetric arc therapy using feature-
based database mining. Journal of applied clinical medical physics. 2014;15(2):4596. 
20. Zhu X, Ge Y, Li T, Thongphiew D, Yin FF, Wu QJ. A planning quality evaluation tool for prostate 
adaptive IMRT based on machine learning. Medical physics. 2011;38(2):719-726. 
21. Tol JP, Delaney AR, Dahele M, Slotman BJ, Verbakel WF. Evaluation of a knowledge-based planning 
solution for head and neck cancer. International journal of radiation oncology, biology, physics. 
2015;91(3):612-620. 
Predicting minimum achievable dose constraints using in-house KBP models 
Page 14 of 23 
 
22. Powis R, Bird A, Brennan M, et al. Clinical implementation of a knowledge based planning tool for 
prostate VMAT. Radiation oncology (London, England). 2017;12(1):81-017-0814-z. 
23. Cui.W, Yan.H, Fu.G, Dai.J, Li.Y. Predicting dosimetric indices in IMRT planning for lung cancer 
patients. Biomedical Physics & Engineering Express. 2015;1(4):045208. 
24. Zawadzka A, Nesteruk M, Brzozowska B, Kukolowicz PF. Method of predicting the mean lung dose 
based on a patients anatomy and dose-volume histograms. Medical dosimetry : official journal of the 
American Association of Medical Dosimetrists. 2017;42(1):57-62. 
25. Zhuang H, Yuan Z, Chang JY, et al. Radiation pneumonitis in patients with non--small-cell lung cancer 
treated with erlotinib concurrent with thoracic radiotherapy. J Thorac Oncol. 2014;9(6):882-885. 
26. Oh D, Ahn YC, Park HC, Lim DH, Han Y. Prediction of radiation pneumonitis following high-dose 
thoracic radiation therapy by 3 Gy/fraction for non-small cell lung cancer: analysis of clinical and 
dosimetric factors [published online ahead of print 2009/02/03]. Jpn J Clin Oncol. 2009;39(3):151-157. 
27. Ren C, Ji T, Liu T, Dang J, Li G. The risk and predictors for severe radiation pneumonitis in lung 
cancer patients treated with thoracic reirradiation [published online ahead of print 2018/04/16]. Radiat 
Oncol. 2018;13(1):69. 
28. Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment-
related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with 
concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT) [published online 
ahead of print 2006/09/25]. Int J Radiat Oncol Biol Phys. 2006;66(5):1399-1407. 
29. Olofssn N. Evaluation of IMRT beam complexity metrics to be used in the IMRT QA process. 
2012:30. 
30. Crowe SB, Kairn T, Kenny J, et al. Treatment plan complexity metrics for predicting IMRT pre-
treatment quality assurance results [published online ahead of print 2014/05/09]. Australas Phys Eng 
Sci Med. 2014;37(3):475-482. 
31. Reinard JC. Communication Research Statistics. SAGE Publications; 2006. 
32. Mayles P, Nahum A, J.C R. Handbook of Radiotherapy Physics: Theory and Practice. New York 
London: Taylor and Francis; 2007. 
33. Zhang X, Li X, Quan EM, Pan X, Li Y. A methodology for automatic intensity-modulated radiation 
treatment planning for lung cancer [published online ahead of print 2011/06/08]. Phys Med Biol. 
2011;56(13):3873-3893. 
34. Quan EM, Chang JY, Liao Z, et al. Automated volumetric modulated Arc therapy treatment planning 
for stage III lung cancer: how does it compare with intensity-modulated radio therapy? Int J Radiat 
Oncol Biol Phys. 2012;84(1):e69-76. 
35. Della Gala G, Dirkx MLP, Hoekstra N, et al. Fully automated VMAT treatment planning for advanced-
stage NSCLC patients. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et 
al]. 2017;193(5):402-409. 
36. Webb S. Use of a quantitative index of beam modulation to characterize dose conformality: illustration 
by a comparison of full beamlet IMRT, few-segment IMRT (fsIMRT) and conformal unmodulated 
radiotherapy. Phys Med Biol. 2003;48(14):2051-2062. 
37. Abdellatif A, Gaede S. Control point analysis comparison for 3 different treatment planning and 
delivery complexity levels using a commercial 3-dimensional diode array [published online ahead of 
print 2014/01/27]. Med Dosim. 2014;39(2):174-179. 
38. Zhen H, Nelms BE, Tome WA. Moving from gamma passing rates to patient DVH-based QA metrics 
in pretreatment dose QA. Med Phys. 2011;38(10):5477-5489. 
39. Younge KC, Roberts D, Janes LA, Anderson C, Moran JM, Matuszak MM. Predicting deliverability of 
volumetric-modulated arc therapy (VMAT) plans using aperture complexity analysis [published online 







Predicting minimum achievable dose constraints using in-house KBP models 
Page 15 of 23 
 
Table 1. Treatment planning objective used for planning NSCLC patients at our clinic. 
Volume Parameters Clinical constraints 
Spinal Cord PRV D0.01cc < 45 Gy 
PTV V95 ≥ 99 % 
V107 < 1.8 cc 
Lungs-GTV 
 
V5Gy < 60 % 
V20Gy < 35 % 
Heart V30Gy < 45 % 
Mean Dose < 26 Gy 
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Table 2. Mean and standard deviation of the differences between achieved and predicted 
dose-volume parameters for lung before and after implementation of model. The minimum 
achievable values for each dose-volume parameter were predicted prior to plan optimisation 
using Eclipse Scripting Application Plugg-In (ESAPI). 
Dose-volume 
parameter 
Before model After model p value 
Mean SD Mean SD 
V5 10.8 % 7.1 % 5.9 % 4.6 % 0.007 
V20 4.0 % 3.1 % 2.7 % 2.1 % 0.038 
MLD 2.5 Gy 1.6 Gy 1.6 Gy 1.0 Gy 0.012 
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Table 3. Comparison of treatment plan complexity measurements for the original and re-
planned plans. Mean, standard deviation, and p values for different parameters. 
Parameters Original Plan SD Re-planned Plan SD p value 
MU/Gy 236.6 29.0 253.4 29.4 0.0002 
MU/Degree 1.8 0.2 2.0 0.2 0.0001 
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Figure 1: Displaying the total lung volume excluding GTV (volume V2) in magenta 
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Figure 2: The plots showing training and verification data and the linear line showing 

































































Predicting minimum achievable dose constraints using in-house KBP models 
Page 20 of 23 
 
 
Figure 3: Plots A, B and C showing reduction plan variability in plans produced after 
the models compared for V5, V20 and MLD respectively. The original plans were 
planned without model predicted values whereas, achieved values were obtained by 
re-optimizing plans with the model predicted values. Three separate models were 
produced for each dose-volume parameter shown in figure 2, using residual lung 
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the plan optimisation and the predicted values for each parameter were entered in 
optimiser. 
  
Predicting minimum achievable dose constraints using in-house KBP models 




Figure 4: Showing difference in dose-volume parameters before and after the 
model. Concurrent reduction was seen in all the dosimetric parameters studied V5 
(A), V20 (B) and MLD (C) after the model. The achievable dosimetric parameters 
were determined using the models prior to optimisation and the predicted values 
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Figure 5: Showing difference in dose-volume parameters before and after the model 
for 66Gy in 33 fractions (A) and 60Gy in 30 fractions (B) prescriptions. The 
normalised model was verified using ten plans, minimum achievable doses were 
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